ENTHYMIC Trademark

Trademark Overview


On Thursday, February 28, 2019, a trademark application was filed for ENTHYMIC with the United States Patent and Trademark Office. The USPTO has given the ENTHYMIC trademark a serial number of 88319644. The federal status of this trademark filing is REGISTERED as of Tuesday, March 10, 2020. This trademark is owned by Enzyvant Therapeutics GmbH. The ENTHYMIC trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment of pediatric congenital athymia and thymus gland diseases, disorders and conditions, and immune deficiency related thereto; pharmaceutical preparations for human use, namely, tissue-based regenerative therapy to treat pediatric congenital athymia and thymus gland diseases, disorders and conditions, and immune deficiency related thereto; biologic preparations for medical and therapeutic purposes for the treatment of pediatric congenital athymia and thymus gland diseases, disorders and conditions, and immune deficiency related thereto; biologic preparations for medical and therapeutic purposes, namely, tissue-based regenerative therapy to treat pediatric congenital athymia and thymus gland diseases, disorders and conditions, and immune deficiency related thereto
enthymic

General Information


Serial Number88319644
Word MarkENTHYMIC
Filing DateThursday, February 28, 2019
Status700 - REGISTERED
Status DateTuesday, March 10, 2020
Registration Number6005358
Registration DateTuesday, March 10, 2020
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 24, 2019

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment of pediatric congenital athymia and thymus gland diseases, disorders and conditions, and immune deficiency related thereto; pharmaceutical preparations for human use, namely, tissue-based regenerative therapy to treat pediatric congenital athymia and thymus gland diseases, disorders and conditions, and immune deficiency related thereto; biologic preparations for medical and therapeutic purposes for the treatment of pediatric congenital athymia and thymus gland diseases, disorders and conditions, and immune deficiency related thereto; biologic preparations for medical and therapeutic purposes, namely, tissue-based regenerative therapy to treat pediatric congenital athymia and thymus gland diseases, disorders and conditions, and immune deficiency related thereto

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, March 19, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEnzyvant Therapeutics GmbH
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressBasel 4051
CH

Party NameEnzyvant Therapeutics GmbH
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressBasel 4051
CH

Party NameEnzyvant Therapeutics GmbH
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressBasel 4051
CH

Trademark Events


Event DateEvent Description
Tuesday, March 10, 2020REGISTERED-PRINCIPAL REGISTER
Tuesday, December 24, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 24, 2019PUBLISHED FOR OPPOSITION
Wednesday, December 4, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, November 20, 2019ASSIGNED TO LIE
Saturday, November 16, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, October 18, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, October 16, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, October 16, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, July 25, 2019ASSIGNED TO EXAMINER
Thursday, May 16, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, May 16, 2019NON-FINAL ACTION E-MAILED
Thursday, May 16, 2019NON-FINAL ACTION WRITTEN
Thursday, May 9, 2019ASSIGNED TO EXAMINER
Tuesday, March 19, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, March 4, 2019NEW APPLICATION ENTERED IN TRAM